NASH limits anti-tumour surveillance in immunotherapy-treated HCC

According to this article by D. Pfister et al., the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH).

0 Comments

Leave a Reply

Your email address will not be published.